{"url_path":"/sec/cing/8-k/2026-07-02/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1862150/0001493152-26-031668-index.html","accession_number":"0001493152-26-031668","cik":"0001862150","ticker":"CING","issuer_name":"Cingulate Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1862150/0001493152-26-031668-index.html","primary_entity_key":"0001862150","primary_entity_name":"Cingulate Inc."},"word_count":252,"has_tables":true,"body_markdown":"**Item\n5.02.**\n**Departure\nof Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**\n\n \n\nOn\nJune 30, 2026, Cingulate Therapeutics LLC (“CTx”), a wholly owned subsidiary of Cingulate Inc. (the “Company”),\nentered into an amendment (the “Amendment”) to the Employment Agreement between Matthew N. Brams, Executive Vice President\nand Chief Medical Officer, and CTx, effective January\n1, 2026. Pursuant to the Amendment, the Trial Period for Mr. Brams’ full-time employment was extended from June 30, 2026 to September\n30, 2026.\n\n \n\nThe\nforegoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is\nfiled herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.\n\n \n\n**Item****7.01.**\n**Regulation FD\nDisclosure.**\n\n \n\nOn\nJuly 2, 2026, the Company issued a press release announcing its selection for membership in the Russell 3000E® Index. A copy\nof the press release is furnished as Exhibits 99.1 to this Current Report on Form 8-K.\n\n \n\nThe\ninformation set forth under this Item 7.01, including Exhibits 99.1, of this Current Report on Form 8-K is not deemed to be “filed”\nfor purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall this Item 7.01\nand Exhibit 99.1 be incorporated by reference into the Company’s filings under the Securities Act of 1933, as amended, or the Exchange\nAct, except as expressly set forth by specific reference in such future filing."}